Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating armodafinil for excessive sleepiness in mild to moderate traumatic brain injury was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Armodafinil (armodafinil)

Snippet

Sponsor: Cephalon, Inc. | Conditions: Traumatic Brain Injury | Phase 3 | Status: TERMINATED | Results posted: 2013-10-18